Global Biopharmaceutical Company - Bristol Myers Squibb

Our R&D Team  >

Learn more about the backgrounds, scientific pursuits and personal interests of members of our research team.

2022 First Quarter Results  >

Bristol Myers Squibb reports first quarter revenues of $11.6 Billion; GAAP EPS of $0.59 and non-GAAP EPS of $1.96 which include net impact of ($0.10) per share due to acquired IPRD charges partially offset by licensing income. Read more, including important cautionary statements about forward-looking information.

Latest FDA Approval >

Bristol Myers Squibb’s Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive hypertrophic cardiomyopathy (obstructive HCM).

Survivorship Today

Emmy winner Sterling K. Brown explores cancer survivorship during a global pandemic.

Learn More >

Moving forward.


We’re looking for people who want to change lives.  Join us as we transform patients’ lives through science. 


Learn more about how we strive to produce sustained strong performance and shareholder value.

Looking for Answers?

Quick links to helpful resources.

Clinical Trial Information for Researchers
Clinical trials and research are a critical part of bringing new medicines to patients.

Medical Information for Healthcare Providers
Information and resources to assist with caring for patients.

Help Paying for Your Medicines
If you are a patient in the U.S. struggling to understand your coverage or pay for your medication, we may be able to help.